Table 4.
Neutralization sensitivity to monoclonal antibodies, sCD4 and anti-CD4
| Env clones | b6 | b12 | 2G12 | 17b | 2F5 | 4E10 | sCD4 | SIM.2* |
|---|---|---|---|---|---|---|---|---|
| 2.J8 | >6.66 | 2.23 | >6.66 | >6.66 | >6.66 | 0.34 | 3.66 | 120 |
| 2.J9 | >6.66 | 2.16 | >6.66 | >6.66 | >6.66 | 0.38 | 3.27 | 104 |
| 2-3.J4 | >6.66 | 1.97 | >6.66 | >6.66 | >6.66 | 3.36 | >6.66 | 260 |
| 2-3.J7 | >6.66 | 2.19 | >6.66 | >6.66 | >6.66 | 5.85 | >6.66 | 260 |
| 2-3.J17 | >6.66 | 2.04 | >6.66 | >6.66 | >6.66 | 4.85 | >6.66 | 106 |
| 2-3.J18 | >6.66 | 0.5 | >6.66 | 5.1 | >6.66 | 4.5 | >6.66 | 37 |
| 2-5.J3 | >6.66 | 0.29 | >6.66 | >6.66 | >6.66 | 2.69 | >6.66 | 201 |
| 2-5.J11 | >6.66 | 0.21 | >6.66 | >6.66 | >6.66 | 0.32 | 6.05 | 152 |
| 3.J16 | >6.66 | >6.66 | 4.20 | >6.66 | >6.66 | 0.23 | 0.54 | 103 |
| 3-3.J9 | >6.66 | >6.66 | 0.18 | 2.9 | >6.66 | 0.3 | 0.1 | 76 |
| 3-5.J25 | >6.66 | >6.66 | 4.85 | >6.66 | >6.66 | 2.6 | 3.3 | 106 |
| 3-5.J38 | >6.66 | >6.66 | 4.30 | >6.66 | >6.66 | 2.22 | >6.66 | 79 |
| 4.J2 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 0.28 | 0.5 | 10 |
| 4.J22 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 4 | >6.66 | 138 |
| 4.J27 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 5.28 | >6.66 | 142 |
| 4-2.J41 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 2.64 | 2.28 | 164 |
| 4-2.J45 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 3.94 | 2.53 | 50 |
| 4-2.J42b | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 5 | >6.66 | 224 |
| 4-2.J45b | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 6.2 | >6.66 | 265 |
| 4-2.J46b | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 240 |
| 4-2.J47b | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 6.5 | >6.66 | 212 |
| 4-5.J5 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 334 |
| 5.J41 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 0.29 | 0.5 | 114 |
| 5-3.J2 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 5.6 | >6.66 | 119 |
| 5-3.J4 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 119 |
| 5-3.J5 | 5.9 | >6.66 | >6.66 | >6.66 | >6.66 | 5.66 | >6.66 | 210 |
| 5-3.J9 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 222 |
| 5-4.J16 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 2.32 | 2.94 | 320 |
| 5-4.J18 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 2.52 | >6.66 | 157 |
| 5-4.J22 | 2.5 | >6.66 | >6.66 | >6.66 | >6.66 | 0.24 | 0.23 | 44 |
| 5-4.J49 | 5.9 | >6.66 | >6.66 | >6.66 | >6.66 | 0.52 | 0.53 | 121 |
| 11.J25 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 0.34 | 3 | 99 |
| 11.J28 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 0.32 | 2.4 | 88 |
| 11-3.J3 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 5.64 | >6.66 | 548 |
| 11-3.J9 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 3.35 | >6.66 | 555 |
| 11-3.J16 | >6.66 | 6.05 | >6.66 | >6.66 | >6.66 | 3.25 | >6.66 | 585 |
| 11-5.J12 | >6.66 | >6.66 | >6.66 | >6.66 | >6.66 | 2.67 | >6.66 | 571 |
Values are concentrations resulting 50% reduction in relative luminescence unit (RLU) as an indicator of neutralization sensitivity in TZM-bl cells following infection with pseudoviruses with 200TCID50. The IC50 values are average of two independent assays wherein each assay was done in duplicates. * The values corresponding to anti-CD4 SIM.2 is hybridoma fluid are reciprocal dilutions giving 50% reduction in relative luminescence unit (RLU).